Symeres has appointed Gabriella Gentile as Chief Operating Officer, strengthening its executive team as the company pursues ambitious transatlantic growth plans.
Gabriella brings over 25 years of international experience across the pharmaceutical, medical device and services sectors. She has held senior roles at Catalent, Roche and Aptuit, where she led transformation programmes focused on operational performance, lean methodologies and change management.
In her new role, Gabriella will lead the transformation of global operations at Symeres, expanding capabilities across the pharmaceutical value chain from inception to investigational new drug. She will focus on aligning operations with measurable performance outcomes, reinforcing Symeres’ commitment to quality and customer satisfaction.
Gabriella said: “I’m delighted to join Symeres at this exciting time in their growth. Symeres operates under a cultural philosophy of openness and transparency, and I look forward to being part of developing new next-generation therapies.”
Guillaume Jetten, CEO of Symeres, explained: “I’m delighted that Gabriella has accepted this position. Gabriella brings a set of highly relevant skills and experience from both her background in medicinal chemistry, but also her decades of large Pharma and biotech experience that will support the future growth plans of Symeres.”
Most recently, Gabriella served as global improvement director at Catalent, where she implemented standardised operational frameworks across multiple sites. Prior to that, she consulted independently on global change and operational excellence programmes.
Her appointment marks a key milestone in Symeres’ strategy to bridge European innovation with American market presence.
